PDE7B and hepatocellular carcinoma: Furthermore, PDE7B might collaboratively enhance the impact of sorafenib in combination with chemotherapy via a specific mechanism, and thus could serve as the promising biomarker and the therapeutic target for the prognosis and immunotherapy of HCC.